4.7 Review

How to Solve the Conundrum of Heparin-Induced Thrombocytopenia during Cardiopulmonary Bypass

期刊

JOURNAL OF CLINICAL MEDICINE
卷 12, 期 3, 页码 -

出版社

MDPI
DOI: 10.3390/jcm12030786

关键词

cardiac surgery; cardiopulmonary bypass; intraoperative management; heparin-induced thrombocytopenia syndrome; direct thrombin inhibitor; antiplatelet therapy

向作者/读者索取更多资源

Heparin-induced thrombocytopenia (HIT) is a severe adverse drug reaction in cardiac surgery involving heparin. It causes immune-mediated thrombocytopenia leading to thrombotic events. Anti-PF4/H antibodies and platelet aggregation tests confirm the diagnosis. Patients with HIT in cardiac surgery face high risks and specific challenges. An institutional protocol has been developed for managing HIT in different phases, including the use of non-heparin anticoagulants and potent antiplatelet drugs.
Heparin-induced thrombocytopenia (HIT) is a major issue in cardiac surgery requiring cardiopulmonary bypass (CPB). HIT represents a severe adverse drug reaction after heparin administration. It consists of immune-mediated thrombocytopenia paradoxically leading to thrombotic events. Detection of antibodies against platelets factor 4/heparin (anti-PF4/H) and aggregation of platelets in the presence of heparin in functional in vitro tests confirm the diagnosis. Patients suffering from HIT and requiring cardiac surgery are at high risk of lethal complications and present specific challenges. Four distinct phases are described in the usual HIT timeline, and the anticoagulation strategy chosen for CPB depends on the phase in which the patient is categorized. In this sense, we developed an institutional protocol covering each phase. It consisted of the use of a non-heparin anticoagulant such as bivalirudin, or the association of unfractionated heparin (UFH) with a potent antiplatelet drug such as tirofiban or cangrelor. Temporary reduction of anti-PF4 with intravenous immunoglobulins (IvIg) has recently been described as a complementary strategy. In this article, we briefly described the pathophysiology of HIT and focused on the various strategies that can be applied to safely manage CPB in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据